Celadon Pharmaceuticals (CEL) Stock Chart & Stock Price History GBX 4.82 +0.33 (+7.22%) As of 11:53 AM Eastern Add Compare Share Share Chart Stock AnalysisChartCompetitorsHeadlinesBuy This Stock Celadon Pharmaceuticals Stock Price Performance The Celadon Pharmaceuticals (CEL) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 95.03%, with a year-to-date return of -65.54%. In the past month, the stock has decreased 24.61%, reflecting recent market activity. As of the latest close, Celadon Pharmaceuticals traded at GBX 5 with a market cap of £3.07 million and volume of 214,134 shares. Receive CEL Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-19.58%1 Month Performance-24.61%3 Month Performance-71.19%Year-To-Date Performance-65.54%1 Year Performance-95.03% CEL Stock Chart for Wednesday, May, 21, 2025 CEL Chart by TradingView Celadon Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/21/2025GBX 5GBX 4.83-3.50%GBX 5GBX 4132,207 shs£2.96 million05/20/2025GBX 4.55GBX 5+9.89%GBX 5GBX 4214,134 shs£3.07 million05/19/2025GBX 6GBX 4.55-24.17%GBX 5GBX 3.10495,284 shs£2.79 million05/16/2025GBX 6GBX 6GBX 6GBX 4292,083 shs£3.68 million05/15/2025GBX 6GBX 6GBX 6GBX 45,409 shs£3.68 million05/14/2025GBX 5GBX 6+20.00%GBX 6GBX 4.559,029 shs£3.68 million05/13/2025GBX 5GBX 5GBX 5.40GBX 433,106 shs£3.07 million05/12/2025GBX 5GBX 5GBX 5.40GBX 433,106 shs£3.07 million05/09/2025GBX 5GBX 5GBX 5GBX 4.5042 shs£3.07 million05/08/2025GBX 5GBX 5GBX 5GBX 4.3714,460 shs£3.07 million Get the Latest News and Ratings for CEL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 05/07/2025GBX 5GBX 5GBX 5GBX 416,700 shs£3.07 million05/06/2025GBX 4.34GBX 5+15.21%GBX 5GBX 4.3776,167 shs£3.07 million05/05/2025GBX 4.34GBX 4.34GBX 5GBX 415,769 shs£2.66 million05/02/2025GBX 5GBX 4.34-13.20%GBX 5GBX 415,769 shs£2.66 million05/01/2025GBX 5.70GBX 5-12.28%GBX 6GBX 4.1255,732 shs£3.07 million04/30/2025GBX 6.56GBX 5.70-13.04%GBX 5.72GBX 422,698 shs£3.50 million04/29/2025GBX 6.78GBX 6.56-3.32%GBX 7GBX 617,151 shs£4.02 million04/28/2025GBX 7GBX 6.78-3.14%GBX 6.78GBX 6.5015,053 shs£4.16 million04/25/2025GBX 6GBX 7+16.67%GBX 7.15GBX 713,220 shs£4.29 million04/24/2025GBX 6.80GBX 6-11.76%GBX 7GBX 620,586 shs£3.68 million04/23/2025GBX 7GBX 6.80-2.86%GBX 7GBX 613,095 shs£4.17 million04/22/2025GBX 6.40GBX 7+9.37%GBX 7GBX 631,309 shs£4.29 million04/21/2025GBX 6.40GBX 6.40GBX 6.99GBX 6.10172,648 shs£3.93 million Related Companies Cambridge Nutritional Sciences Stock Chart Beacon Energy Stock Chart Fox Marble Stock Chart Vodafone Group Public Stock Chart BT Group Stock Chart BBGI Global Infrastructure Stock Chart Pacific Horizon Investment Trust Stock Chart Provexis Stock Chart Argent BioPharma Stock Chart N4 Pharma Stock Chart Receive CEL Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (LON:CEL) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.